- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schering extends deal with NeXstar
German contrast agent firm Schering has extended its ongoing R&Dcollaboration with pharmaceutical developer NeXstar of Boulder,CO, for the development of in vivo imaging agents using NeXstar'sSelex combinatorial chemistry process. Schering increased
German contrast agent firm Schering has extended its ongoing R&Dcollaboration with pharmaceutical developer NeXstar of Boulder,CO, for the development of in vivo imaging agents using NeXstar'sSelex combinatorial chemistry process. Schering increased itsresearch payments to NeXstar to $2.4 million a year from $1 milliona year as part of the deal.
Under the collaboration, NeXstar is using the Selex processto develop aptamers, which are short stretches of modified DNAor RNA that can bind to diagnostic targets in the body. Thesetargets can be identified by imaging modalities, and Scheringhas specified several cardiac and oncology applications it isinterested in pursuing.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
